Melbourne (Australia), Brussels (Belgium) – 18th of October 2018. Telix Pharmaceuticals Limited has today announced that the Company has received its first European Competent Authority (CA) approval to commence a clinical trial of TLX101 for the treatment of recurrent glioblastoma. The full media release can be accessed here.